Pharmacogenomics of serious adverse drug reactions in pediatric oncology
Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40% of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long...
Gespeichert in:
| Veröffentlicht in: | Journal of population therapeutics and clinical pharmacology 2011, Vol.18, p.e134-e151 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e151 |
|---|---|
| container_issue | |
| container_start_page | e134 |
| container_title | Journal of population therapeutics and clinical pharmacology |
| container_volume | 18 |
| creator | Ross, Colin J D Visscher, Henk Rassekh, S Rod Castro-Pastrana, Lucila I Shereck, Evan Carleton, Bruce Hayden, Michael R |
| description | Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40% of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long-term sequelae. ADRs are often more frequent and more severe in children, and the consequences for children who experience a severe ADR can be catastrophic. Pharmacogenomics has the potential to improve the safety of these drugs. This review highlights severe ADRs that can occur in cancer therapy that are more frequent and more severe in children, and the pharmacogenomics research that aims to understand, predict, and ultimately prevent these severe reactions. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_860882535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>860882535</sourcerecordid><originalsourceid>FETCH-LOGICAL-p210t-3bc9fc443cd41419b73894ba4a09f965b021c5ffaf1b9b583a18fdd8f76f50113</originalsourceid><addsrcrecordid>eNo1j0tLxDAYRYMgzjDOX5DsXBXybJOlDOoIA7rQdfnyqpG2qUkrzL-34Hg3d3M43HuFtkzWtFKNoBu0L-WLrOFa6YbdoA2jom5qIrbo-PYJeQCbOj-mIdqCU8DF55iWgsH9-Fw8dnnpcPZg55jGguOIJ-8izDlanEab-tSdb9F1gL74_aV36OPp8f1wrE6vzy-Hh1M1MUrmihurgxWCWyeooNo0XGlhQADRQdfSEEatDAECNdpIxYGq4JwKTR0koZTv0P2fd8rpe_FlbodYrO97GP26uVU1UYpJLlfy7kIuZvCunXIcIJ_b__P8F2JTVkM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>860882535</pqid></control><display><type>article</type><title>Pharmacogenomics of serious adverse drug reactions in pediatric oncology</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ross, Colin J D ; Visscher, Henk ; Rassekh, S Rod ; Castro-Pastrana, Lucila I ; Shereck, Evan ; Carleton, Bruce ; Hayden, Michael R</creator><creatorcontrib>Ross, Colin J D ; Visscher, Henk ; Rassekh, S Rod ; Castro-Pastrana, Lucila I ; Shereck, Evan ; Carleton, Bruce ; Hayden, Michael R</creatorcontrib><description>Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40% of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long-term sequelae. ADRs are often more frequent and more severe in children, and the consequences for children who experience a severe ADR can be catastrophic. Pharmacogenomics has the potential to improve the safety of these drugs. This review highlights severe ADRs that can occur in cancer therapy that are more frequent and more severe in children, and the pharmacogenomics research that aims to understand, predict, and ultimately prevent these severe reactions.</description><identifier>EISSN: 2561-8741</identifier><identifier>PMID: 21467604</identifier><language>eng</language><publisher>Australia</publisher><subject>Anthracyclines - adverse effects ; Antineoplastic Agents - adverse effects ; Child ; Cisplatin - adverse effects ; Humans ; Methotrexate - adverse effects ; Neoplasms - drug therapy ; Peripheral Nervous System Diseases - chemically induced ; Pharmacogenetics ; Vincristine - adverse effects ; Warfarin - adverse effects</subject><ispartof>Journal of population therapeutics and clinical pharmacology, 2011, Vol.18, p.e134-e151</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21467604$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ross, Colin J D</creatorcontrib><creatorcontrib>Visscher, Henk</creatorcontrib><creatorcontrib>Rassekh, S Rod</creatorcontrib><creatorcontrib>Castro-Pastrana, Lucila I</creatorcontrib><creatorcontrib>Shereck, Evan</creatorcontrib><creatorcontrib>Carleton, Bruce</creatorcontrib><creatorcontrib>Hayden, Michael R</creatorcontrib><title>Pharmacogenomics of serious adverse drug reactions in pediatric oncology</title><title>Journal of population therapeutics and clinical pharmacology</title><addtitle>J Popul Ther Clin Pharmacol</addtitle><description>Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40% of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long-term sequelae. ADRs are often more frequent and more severe in children, and the consequences for children who experience a severe ADR can be catastrophic. Pharmacogenomics has the potential to improve the safety of these drugs. This review highlights severe ADRs that can occur in cancer therapy that are more frequent and more severe in children, and the pharmacogenomics research that aims to understand, predict, and ultimately prevent these severe reactions.</description><subject>Anthracyclines - adverse effects</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Child</subject><subject>Cisplatin - adverse effects</subject><subject>Humans</subject><subject>Methotrexate - adverse effects</subject><subject>Neoplasms - drug therapy</subject><subject>Peripheral Nervous System Diseases - chemically induced</subject><subject>Pharmacogenetics</subject><subject>Vincristine - adverse effects</subject><subject>Warfarin - adverse effects</subject><issn>2561-8741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j0tLxDAYRYMgzjDOX5DsXBXybJOlDOoIA7rQdfnyqpG2qUkrzL-34Hg3d3M43HuFtkzWtFKNoBu0L-WLrOFa6YbdoA2jom5qIrbo-PYJeQCbOj-mIdqCU8DF55iWgsH9-Fw8dnnpcPZg55jGguOIJ-8izDlanEab-tSdb9F1gL74_aV36OPp8f1wrE6vzy-Hh1M1MUrmihurgxWCWyeooNo0XGlhQADRQdfSEEatDAECNdpIxYGq4JwKTR0koZTv0P2fd8rpe_FlbodYrO97GP26uVU1UYpJLlfy7kIuZvCunXIcIJ_b__P8F2JTVkM</recordid><startdate>2011</startdate><enddate>2011</enddate><creator>Ross, Colin J D</creator><creator>Visscher, Henk</creator><creator>Rassekh, S Rod</creator><creator>Castro-Pastrana, Lucila I</creator><creator>Shereck, Evan</creator><creator>Carleton, Bruce</creator><creator>Hayden, Michael R</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>2011</creationdate><title>Pharmacogenomics of serious adverse drug reactions in pediatric oncology</title><author>Ross, Colin J D ; Visscher, Henk ; Rassekh, S Rod ; Castro-Pastrana, Lucila I ; Shereck, Evan ; Carleton, Bruce ; Hayden, Michael R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p210t-3bc9fc443cd41419b73894ba4a09f965b021c5ffaf1b9b583a18fdd8f76f50113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Anthracyclines - adverse effects</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Child</topic><topic>Cisplatin - adverse effects</topic><topic>Humans</topic><topic>Methotrexate - adverse effects</topic><topic>Neoplasms - drug therapy</topic><topic>Peripheral Nervous System Diseases - chemically induced</topic><topic>Pharmacogenetics</topic><topic>Vincristine - adverse effects</topic><topic>Warfarin - adverse effects</topic><toplevel>online_resources</toplevel><creatorcontrib>Ross, Colin J D</creatorcontrib><creatorcontrib>Visscher, Henk</creatorcontrib><creatorcontrib>Rassekh, S Rod</creatorcontrib><creatorcontrib>Castro-Pastrana, Lucila I</creatorcontrib><creatorcontrib>Shereck, Evan</creatorcontrib><creatorcontrib>Carleton, Bruce</creatorcontrib><creatorcontrib>Hayden, Michael R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of population therapeutics and clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ross, Colin J D</au><au>Visscher, Henk</au><au>Rassekh, S Rod</au><au>Castro-Pastrana, Lucila I</au><au>Shereck, Evan</au><au>Carleton, Bruce</au><au>Hayden, Michael R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pharmacogenomics of serious adverse drug reactions in pediatric oncology</atitle><jtitle>Journal of population therapeutics and clinical pharmacology</jtitle><addtitle>J Popul Ther Clin Pharmacol</addtitle><date>2011</date><risdate>2011</risdate><volume>18</volume><spage>e134</spage><epage>e151</epage><pages>e134-e151</pages><eissn>2561-8741</eissn><abstract>Adverse drug reactions (ADRs) rank as one of the top ten leading causes of death and illness in the developed world. In cancer therapy, more patients are surviving cancer than ever before, but 40% of cancer survivors suffer life-threatening or permanently disabling severe ADRs and are left with long-term sequelae. ADRs are often more frequent and more severe in children, and the consequences for children who experience a severe ADR can be catastrophic. Pharmacogenomics has the potential to improve the safety of these drugs. This review highlights severe ADRs that can occur in cancer therapy that are more frequent and more severe in children, and the pharmacogenomics research that aims to understand, predict, and ultimately prevent these severe reactions.</abstract><cop>Australia</cop><pmid>21467604</pmid></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 2561-8741 |
| ispartof | Journal of population therapeutics and clinical pharmacology, 2011, Vol.18, p.e134-e151 |
| issn | 2561-8741 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_860882535 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Anthracyclines - adverse effects Antineoplastic Agents - adverse effects Child Cisplatin - adverse effects Humans Methotrexate - adverse effects Neoplasms - drug therapy Peripheral Nervous System Diseases - chemically induced Pharmacogenetics Vincristine - adverse effects Warfarin - adverse effects |
| title | Pharmacogenomics of serious adverse drug reactions in pediatric oncology |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T21%3A15%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pharmacogenomics%20of%20serious%20adverse%20drug%20reactions%20in%20pediatric%20oncology&rft.jtitle=Journal%20of%20population%20therapeutics%20and%20clinical%20pharmacology&rft.au=Ross,%20Colin%20J%20D&rft.date=2011&rft.volume=18&rft.spage=e134&rft.epage=e151&rft.pages=e134-e151&rft.eissn=2561-8741&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E860882535%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=860882535&rft_id=info:pmid/21467604&rfr_iscdi=true |